Myeloma Multiple
Conditions
Brief summary
This is a single-center, observational study in patients with multiple myeloma, conducted both retrospectively and prospectively. The study aims to improve understanding of the biological and clinical factors that influence disease progression, relapse, and treatment resistance. The study will integrate clinical information with advanced genomic and molecular analyses, including whole genome and RNA sequencing, as well as circulating tumor markers, to identify features linked to therapy response and disease behavior. All data will be securely stored, maintaining patient confidentiality, to build a comprehensive map of multiple myeloma that may guide more personalized future treatments.
Interventions
None listed
Sponsors
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age 18+ * Signed CI for study partecipation and personal data processing. * Diagnosis of monoclonal gammopathy, or of acrive multiple myaloma (NDMM/RMM/RRMM)
Exclusion criteria
* None
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response assessment (according to IMWG criteria) and / or disease progression (PD) | 12 months after the start of therapy, in pre-neoplastic groups , only PD will be considered |
Secondary
| Measure | Time frame |
|---|---|
| Response to treatment <VGPR (according to IMWG criteria) and/or disease progression (PD) | From baseline to disease progression (PD), assessed up to 24 months. |
| Presence and/or absence of "secondary" tumor clone(s) | From baseline to disease progression (PD), assessed up to 24 months. |
| Presence and/or absence of differences between baseline characteristics and progression features | From baseline to disease progression (PD), assessed up to 24 months. |
Countries
Italy
Contacts
CONTACTCarolina Terragna, MD
Outcome results
None listed